menu
search
Skip to main content

Advancing healthcare one investment at a time

930789324

As one of the largest and longest-tenured health care investors in the world, we offer both capital and strategic guidance to bring breakthrough biotechnology to the world. Our private equity experts, with deep scientific backgrounds, partner with remarkable companies that are leading the way with innovations and aiming to raise the bar on standard of care.

UiPath logo

Rayzebio: case study

Rayzebio is a biotechnology company focused on developing targeted radiopharmaceutical drugs for solid tumors in cancers. The team prosecutes diverse sets of binders against clinically validated cancer targets through an iterative process involving in-vitro screening, X-ray crystallography, linker and radiolabeling optimization, and in-vivo screening with molecular imaging and biodistribution analysis.

Our investments

tune Filters 0
highlight_off control_point
cached Reset All
Sector expand_more
Status expand_more
highlight_off
highlight_off
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Health care
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotech
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Information technology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Health care
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology
Sector:
Biotechnology

Wellington looks to understand the science and buys into the vision. They want to be a thought partner, not just a provider of capital.

Dr. Axel Hoos
CEO, Scorpion Therapeutics
95039-hoos-541x403

Dr. Axel Hoos is the CEO of Scorpion Therapeutics, which is a portfolio company that Wellington has invested in. This statement about Wellington reflects a personal opinion that may not be shared by others. There has been no compensation provided for such statements.

News

WAV-team_316x316
Alternatives Private investing Venture capital Private portfolio companies

Forbes | Wellington Access Ventures Raises $150 Million To Back Underrepresented Founders

Our Wellington Access Ventures Team sat down with Forbes to discuss the final close of the private investing platform’s first early-stage venture capital fund and how they look to partner with "the next industry-defining companies."

Source: Forbes

WAV-team_316x316
Press release

Wellington Management announces US$150 million final close for Wellington Venture Investments I

We are pleased to announce the final close of Wellington's first early-stage venture fund focused on investing in large and growing markets like the B2B software, fintech, and consumer sectors.
news-wellington-icapital-158x158
Press release

iCapital® and Wellington Management forge global partnership

iCapital® and Wellington Management Forge Global Partnership to Enhance Access to Institutional-Quality Alternative Investments

Insights

More private investing focus areas

Venture capital

We look to partner with early-stage companies that can become leaders in large and growing markets.

From energy transformation to sustainable cities to next-generation agriculture, we support innovative companies helping to address the impacts of climate change.

To guide late-stage private companies through the finish line and beyond, we leverage our deep industry expertise, resources, and long-term relationships across public and private markets.

Private credit 

We seamlessly combine our extensive private placement experience and deep expertise working with insurers — as one of the largest asset managers for insurance companies globally.

This reflects substantially all portfolio company investments made by Wellington Management’s dedicated private equity portfolios. Due to confidentiality restrictions, some company names cannot be disclosed. Additional information is available upon request. As of February 29, 2024.